Nama's AI scorecard currently rates Eli Lilly Buy (7.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is LLY's P/E ratio?

Eli Lilly trades at a trailing price-to-earnings ratio of 42.4.

When does LLY report earnings?

Eli Lilly's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $11.12.

What is the LLY price target?

The median analyst price target from 29 analysts is $1,508.00, with a range of $930.00 – $1,690.00.

Is LLY Shariah compliant?

Nama's AAOIFI-style screen reads Eli Lilly as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does LLY pay a dividend?

Yes — Eli Lilly's dividend yield is 0.5%.

Nama Insights

Eli Lilly (LLY)

Healthcare · Drug Manufacturers General · NYSE

S&P 500

Eli Lilly (LLY) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $1.21T, a trailing price-to-earnings ratio of 42.4 and a free-cash-flow yield of 0.5%. Over the most recent reported fiscal year, revenue grew 44.7% and free cash flow per share grew 1348.2%. Nama's AI scorecard rates it Buy, 7.3 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 7.3/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Rising · +26.8% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-6.8%

How far the last close sits under the highest price of the past five years.

Market cap	$1.21T
Trailing P/E	42.4
Price / book	30.0
Price / sales	13.9
FCF yield	0.5%
Dividend yield	0.5%
Gross margin	83.6%
Operating margin	51.2%
Net margin	31.9%
Revenue growth (YoY)	+44.7%
Revenue growth (3-yr annual)	+31.7%
EPS growth (YoY)	+86.2%
FCF/share growth (YoY)	+1348.2%
Beta	0.5
Exchange	NYSE
Sector	Healthcare
Industry	Drug Manufacturers General

LLY earnings

Next report: Feb 3, 2027 (Q4 2026, EPS estimate $11.12). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$7.48	$6.35	+17.8%	$24.40B
Q2 2026	Aug 5, 2026	$8.38	$6.58	+27.4%	$22.97B
Q1 2026	Apr 30, 2026	$8.55	$6.79	+25.9%	$19.80B
Q4 2025	Feb 4, 2026	$7.54	$6.91	+9.1%	$19.29B

LLY analyst price target

Median target $1,508.00 from 29 analysts, ranging $930.00 – $1,690.00.

Drug Manufacturers General peers

Ticker	Company	Market cap	P/E
JNJ	Johnson & Johnson	$664.95B	25.9
ABBV	AbbVie	$514.92B	22.7
MRK	Merck	$361.73B	47.0
NVS	Novartis	$307.00B	19.0
AZN	AstraZeneca	$289.14B	38.8
AMGN	Amgen	$249.05B	19.9
GILD	Gilead Sciences	$207.00B	—
NVO	Novo Nordisk A/S	$177.74B	11.0

Explore live LLY data on Nama Insights →

Recent Congressional trades

Eli Lilly trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
John Boozman	Senate	Sell	$1,001 - $15,000	Aug 24, 2026
Michael Rulli	House	Sell	$1,001 - $15,000	Aug 7, 2026
Michael Rulli	House	Buy	$1,001 - $15,000	Aug 7, 2026
Michael Rulli	House	Sell	$1,001 - $15,000	Aug 7, 2026
Thomas H Tuberville	Senate	Sell	$15,001 - $50,000	Aug 5, 2026
Alan Armstrong	Senate	Sell	$1,001 - $15,000	Jul 21, 2026
Dan Newhouse	House	Sell	$1,001 - $15,000	Jul 17, 2026
Gilbert Cisneros	House	Buy	$50,001 - $100,000	Jul 2, 2026
Byron Donalds	House	Buy	$1,001 - $15,000	May 13, 2026
Byron Donalds	House	Buy	$1,001 - $15,000	May 13, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	May 8, 2026
Elizabeth Fletcher	House	Sell	$1,001 - $15,000	May 1, 2026

LLY FAQ

Is LLY a buy?: Nama's AI scorecard currently rates Eli Lilly Buy (7.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is LLY's P/E ratio?: Eli Lilly trades at a trailing price-to-earnings ratio of 42.4.
When does LLY report earnings?: Eli Lilly's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $11.12.
What is the LLY price target?: The median analyst price target from 29 analysts is $1,508.00, with a range of $930.00 – $1,690.00.
Is LLY Shariah compliant?: Nama's AAOIFI-style screen reads Eli Lilly as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does LLY pay a dividend?: Yes — Eli Lilly's dividend yield is 0.5%.